Introduction

44
The RTS,S/AS candidate malaria vaccine is under clinical development for possible use 45 in the Expanded Program on Immunization for infants and children in sub-Saharan Africa 46
as an addition to existing preventive and treatment measures, such as insecticide-47 treated bed nets, indoor residual spraying, and intermittent preventive treatment with 48 sulfadoxine-pyrimethamine. 1, 2 The antigen component of the candidate malaria vaccine, 49 RTS,S, consists of repeat sequences of the Plasmodium falciparum circumsporozoite 50 (CS) protein fused to the hepatitis B surface antigen (HBs).
3 Two adjuvant systems have 51 been evaluated with the RTS,S antigen: AS02, which consists of an oil-in-water 52 emulsion with monophosphoryl lipid A (MPL) and Quillaja saponaria Molina, fraction 21 53 (QS21, Antigenics Inc., a wholly owned subsidiary of Agenus Inc., Lexington, MA, USA), 54 as immunostimulants, and AS01, a related liposome-based adjuvant system that also 55 contains MPL and QS21.
3,4 56
Anti-CS antibody titers and, to a lesser extent, CS-specific CD4 + T cells elicited by 57 RTS,S have been identified as immunological markers associated with protection.
5-7 CS-58 specific CD4 + T cells induced by RTS,S produce a mixture of cytokines, such as 59
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As expected from the primed status of the participants in terms of anti-HBs antibody 116 titers, CD4 + T cell frequencies are much higher following stimulation with HBs than with 117 CS (Fig. 3B ). HBs-specific CD4 + T cell responses were detected in all groups after 118 vaccination, with a trend for higher median values in the adjuvanted RTS,S groups. 119
Although some CD8 + T cell proliferation was observed following CS stimulation of 120 peripheral blood mononuclear cells (PBMCs) harvested at screening, no vaccine-121 induced CS-or HBs-specific CD8 + T cell responses were detected in any group (data 122 not shown). 123
Reactogenicity and safety 124
Incidences of all solicited adverse events (AEs), apart from gastrointestinal symptoms, 125 tended to be higher with the adjuvanted antigen than with unadjuvanted RTS,S (Fig. 4) . 126
There was no trend suggesting an increase in solicited AE incidence with subsequent 127 vaccine doses (data not shown). Injection site pain was the most frequently reported 128 solicited local AE in all vaccine groups (Fig. 4) . All grade 3 local AEs resolved within the 129 7-day follow up, except for two separate episodes of grade 3 redness after the first dose 130 7/27 causally related to vaccination were reported by four recipients of RTS,S/AS01 (33.3%), 141 five recipients of RTS,S/AS02 (41.7%), and three recipients of RTS,S/saline (25.0%). 142
Each vaccine-related unsolicited AE occurred in one subject only for each group, except 143 for injection site pruritus (reported in two subjects in the RTS,S/AS01 group), arthralgia 144 (reported in two subjects in the RTS,S/AS01 group), and myalgia (reported in three 145 subjects in the RTS,S/AS01 group). One related unsolicited AE had grade 3 intensity: 146 myalgia, which followed the first dose of RTS,S/AS01 and resolved within 2 days. 147
No serious AEs were reported during the study. No clinically relevant changes in clinical 148 laboratory parameters were reported as AEs or serious AEs. 149
Discussion
150
The present study was designed to evaluate the humoral and cellular immune responses 151 elicited by adjuvanted RTS,S as compared to non-adjuvanted RTS,S in healthy, malaria-152 naïve adults. As priming with hepatitis B vaccine has been shown to influence immune 153 responses against both CS and HBs, 14 the immunological determinants contained in 154 RTS,S, we enrolled subjects with detectable anti-HBs responses (≥10 mIU/ml) in an 155 attempt to ensure baseline comparability. Adjuvantation was shown to strongly enhance 156 immune responses, with RTS,S/AS01 and RTS,S/AS02 eliciting anti-CS antibody GMT 157 responses that were 13-and 6-fold higher, respectively, than the response to non-158 adjuvanted RTS,S. CS-and HBs-specific CD4 + T cell responses were also stronger with 159 the adjuvanted RTS,S formulations as compared to RTS,S/saline, with a trend towards 160 higher CMI responses in the RTS,S/AS01 group. Paradoxically one subject in the saline 161 group showed a CS-specific immune response after dose 1 which decreased over time 162
and was undetectable at study end. We have no clear reason for this. However, 163 although highly improbable, we can't completely rule out the possibility that the subject 164 erroneously received an adjuvanted vaccine at month 0.
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The results of this trial confirm those from a study of malaria-naïve adults conducted in 166 the USA, which reported significantly greater CS-specific humoral immune responses 167 and a tendency towards higher CD4 + T cell responses with RTS,S/AS01 than with 168 RTS,S/AS02. 11 In that study, vaccine efficacy against malaria challenge was 50% with 169 RTS,S/AS01 and 32% with RTS,S/AS02, and significant correlations were found 170 between protection against malaria challenge and both CS-specific antibody responses 171 and CMI responses induced by the RTS,S vaccine.
7,11 CD4 + T cells predominantly 172 expressed CD40L, a co-stimulatory ligand required for T cell help that also induces the 173 differentiation of B cells, 18, 19 and IL-2, a cytokine associated with memory T cells and T 174 cell proliferation and differentiation. 20 There was also a strong association between the 175 frequency of IL-2 producing CD4 + T cells and titers of CS-specific antibodies in the same 176 individual, suggesting that IL-2 may contribute to protection by promoting both cellular 177 and humoral responses.
7 Methods available at the time of the study, however, did not 178 allow for a phenotypic analysis of the CS CD4 + T cell data. 179
Induction of CD4 + T cells directed against P. falciparum CS protein by RTS,S adjuvanted 180
formulations has been shown in clinical field trials in adults and children. 6, 8, 9, [21] [22] [23] No 181 systematic vaccine-induced CD8 + T cell response was detected in PBMCs in our study, 182 which was consistent with other studies that showed RTS,S/AS induces little or no 183 detectable CD8 + T cell response.
6,11,21,24,25
184
The anti-CS humoral immune responses in this study tended to be lower than those 185 observed following administration of three doses of RTS,S/AS01 or RTS,S/AS02 to 186 malaria-experienced children in Africa 13,14 but higher than those in African adults in a 187 high malaria transmission area. 12 Overall, in all studies including the present trial, 188 RTS,S/AS formulations produced robust anti-CS antibody responses, with the AS01 189 adjuvanted vaccine inducing higher responses than the AS02 adjuvanted formulation.
12-
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14 To further assess the quality of the antibody response, the relative avidity of anti-CS 191 antibodies was measured in an ELISA procedure using the chaotropic agent, ammonium 192 thiocyanate. The use of chaotropic agents is based on their ability to dissociate antibody-193 antigen complexes of low avidity while complexes of high avidity remain intact. 26 In The participants were randomized (1:1:1), by a centralized randomization system on the 250 internet administered by the investigator, to receive vaccination at months 0, 1, and 2 251 with lyophilized RTS,S (50 µg) reconstituted with 500 µL of either AS01 A , AS02 B 252 (referred to elsewhere in this paper as AS01 and AS02, respectively), or saline. The 253 RTS,S vaccine has been described previously. 3 The vaccines were administered 254 intramuscularly to the deltoid muscle of the non-dominant arm and vaccine recipients 255
were observed for at least 30 minutes following each vaccination. 256
All laboratory assays were performed at the Center for Vaccinology, Ghent University 257 and Hospital, or at the laboratories of GlaxoSmithKline Vaccines, Rixensart, Belgium, 258 using standardized, validated procedures. 259
Humoral immune response assessments 260
Assessment of anti-CS and anti-HBs antibody titers was conducted on serum samples 261 taken before dose 1 (at enrolment), one month after dose 1 (month 1), one month after 262 dose 2 (month 2), and one month after dose 3 (month 3). Antibodies against CS were 263 measured by evaluating IgG responses to the CS-repeat region, using a standard ELISA12/27 with R32LR as the capture antigen.
The avidity of anti-CS antibodies in sera was assessed at months 1, 2, and 3. The 268 relative avidity of IgG antibodies was determined by ELISA with R32LR as coating 269 antigen. The assay was an adaptation of the anti-CS assay 28 and based on previous 270 methodology on the dissociation of low avidity antibody-antigen complexes by the 271 chaotropic agent, ammonium thiocyanate (NH 4 SCN).
26 After sample addition, formed 272 antigen-antibody complexes were treated with a 1M ammonium thiocyanate solution and 273 remaining complexes were quantified. The result was compared to the concentration 274 obtained when no treatment was applied and expressed as the avidity index, indicating 275 the percentage of antibodies that remained bound to antigens. 276
CMI response assessments 277
Blood samples for CMI response analysis were collected at months 1, 2, and 3. CMI 278 responses to the CS and HBs antigens were assessed using frozen PBMCs, which were 279 AEs were recorded by participants on diary cards during the 7-day follow-up after each 294 vaccination. Information on unsolicited AEs were collected over 30 days after each 295 vaccination. Serious AEs were reported throughout the study. Duration, causality, and 296 outcome of AEs were recorded. All solicited local reactions were considered causally 297 related to vaccination; the relationship of other AEs was classified as possible or not 298 causally related. AE intensity was scored on a scale from 1 to 3. Grade 3 AEs were 299 defined as preventing normal daily activity, apart from grade 3 solicited fever, which was 300 defined as axillary temperature >39.0°C, and grade 3 solicited swelling or redness, 301 defined as diameter >50 mm. Complete blood count, renal (creatinine) and hepatic 302 functional tests (alanine aminotransferase and aspartate aminotransferase) were taken 303 at screening and one month after the third vaccine dose. 304
Statistical analyses 305
A sample size of 10 evaluable subjects per group had 98% power to demonstrate 306 superiority of RTS,S/AS01 over RTS,S/saline, assuming a log standard deviation not 307 exceeding 0.7 and anti-CS GMTs of 5 EU/mL and 143 EU/mL for RTS,S/saline and 308 RTS,S/AS01, respectively, and 91% power to demonstrate superiority of RTS,S/AS02 309 over RTS,S/saline, assuming a log standard deviation not exceeding 0.7 and anti-CS14/27 protocol, with no elimination criteria during the study, and for whom data concerningGMTs were calculated with 95% CIs. The percentages of subjects with seropositive 316 levels of anti-CS antibodies (≥0.5 EU/mL) and seroprotective levels of anti-HBs 317 antibodies (≥10 mIU/mL) were determined. Superiority of RTS,S/AS01 or RTS,S/AS02 318 over RTS,S/saline in terms of anti-CS antibody GMTs one month after the third vaccine 319 dose was evaluated using a 2-sided T-test on the log 10 transformed anti-CS titers 320 Table 4 . Frequency of unsolicited symptoms (reported in more than one subject in a single group) during the 30-day post-vaccination period (total vaccinated cohort). 
Percentage of subjects (95% CI
